Stockreport

Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher

Jaguar Health, Inc.  (JAGX) 
US:NASDAQ Investor Relations: jaguarhealth.gcs-web.com/investor-overview
PDF This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera [Read more]